新华制药
(000756)
| 流通市值：80.00亿 | | | 总市值：112.02亿 |
| 流通股本：4.93亿 | | | 总股本：6.90亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 4,638,804,042.98 | 2,429,825,335.81 | 8,466,309,803.08 | 6,734,166,240.75 |
| 营业收入 | 4,638,804,042.98 | 2,429,825,335.81 | 8,466,309,803.08 | 6,734,166,240.75 |
| 二、营业总成本 | 4,343,477,881.12 | 2,299,988,387.7 | 7,940,307,572.72 | 6,337,089,365.67 |
| 营业成本 | 3,709,265,385.35 | 1,974,290,313.61 | 6,424,760,721.71 | 5,151,913,375.72 |
| 税金及附加 | 34,201,506.79 | 17,878,928.9 | 68,412,881.15 | 51,662,674.6 |
| 销售费用 | 172,609,904.66 | 99,952,491.15 | 584,739,997.94 | 504,223,794.96 |
| 管理费用 | 215,097,968.7 | 94,042,826.77 | 437,070,533.59 | 292,405,195.99 |
| 研发费用 | 202,425,169.04 | 109,788,595.18 | 413,182,811.71 | 326,669,940.69 |
| 财务费用 | 9,877,946.58 | 4,035,232.09 | 12,140,626.62 | 10,214,383.71 |
| 其中:利息费用 | 21,449,091.61 | 10,945,223.03 | 39,739,279.77 | 28,115,663.07 |
| 其中:利息收入 | 4,546,837.79 | 2,409,858.79 | 11,125,515.61 | 8,324,746.77 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | 5,879,082.58 | -760,243.82 | 9,836,416.05 | 8,399,571.55 |
| 资产处置收益 | 1,711,209.17 | 1,760,884.21 | 1,419,533.61 | 1,201,542.62 |
| 资产减值损失(新) | -50,287,533.79 | - | -51,613,568.72 | -48,313,538.64 |
| 信用减值损失(新) | -9,135,931.3 | 100,000 | -9,462,280.63 | -8,073,501.52 |
| 其他收益 | 20,754,218.59 | 12,233,676.46 | 58,188,339.6 | 47,979,403.05 |
| 四、营业利润 | 264,247,207.11 | 143,171,264.96 | 534,370,670.27 | 398,270,352.14 |
| 加:营业外收入 | 2,897,371.44 | 325,013.26 | 8,481,488.89 | 659,426.07 |
| 减:营业外支出 | 3,617,380.47 | 806,901.64 | 9,198,735.84 | 6,012,150.78 |
| 五、利润总额 | 263,527,198.08 | 142,689,376.58 | 533,653,423.32 | 392,917,627.43 |
| 减:所得税费用 | 32,358,726.29 | 27,045,573.46 | 46,938,849.44 | 37,468,356.21 |
| 六、净利润 | 231,168,471.79 | 115,643,803.12 | 486,714,573.88 | 355,449,271.22 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 231,168,471.79 | 115,643,803.12 | 486,714,573.88 | 355,449,271.22 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 223,756,530.43 | 112,095,257.24 | 470,023,746.08 | 344,079,950.67 |
| 少数股东损益 | 7,411,941.36 | 3,548,545.88 | 16,690,827.8 | 11,369,320.55 |
| 扣除非经常损益后的净利润 | 210,859,939.48 | 105,028,074.41 | 448,006,721.77 | 321,411,536.21 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.32 | 0.15 | 0.69 | 0.5 |
| (二)稀释每股收益 | 0.32 | 0.15 | 0.68 | 0.5 |
| 八、其他综合收益 | 14,538,742.98 | -10,645,120.96 | 56,232,510.23 | 74,961,072.66 |
| 归属于母公司股东的其他综合收益 | 14,653,075.21 | -10,573,077.19 | 55,979,397.24 | 75,223,458.18 |
| 九、综合收益总额 | 245,707,214.77 | 104,998,682.16 | 542,947,084.11 | 430,410,343.88 |
| 归属于母公司股东的综合收益总额 | 238,409,605.64 | 101,522,180.05 | 526,003,143.32 | 419,303,408.85 |
| 归属于少数股东的综合收益总额 | 7,297,609.13 | 3,476,502.11 | 16,943,940.79 | 11,106,935.03 |
| 公告日期 | 2025-08-27 | 2025-04-29 | 2025-03-31 | 2024-10-30 |
| 审计意见(境内) | | | 标准无保留意见 | |